業務咨詢
中國:
Email: marketing@www.msjidi.com
業務咨詢專線:400-780-8018
(僅限服務咨詢,其他事宜請撥打川沙總部電話)
川沙總部電話: +86 (21) 5859-1500
海外:
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
ARD-2128 is a bona fide PROTAC androgen receptor (AR) degrader and strongly suppresses AR-regulated genes in a dose- and time-dependent manner in AR+ prostate cancer cell lines.
ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey).
The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.
Reference
Xin Han, et al. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. J Med Chem. 2021 Sep 9;64(17):12831-12854. doi: 10.1021/acs.jmedchem.1c00882.
川沙總部
地址: 上海市浦東新區川大路585號
郵編: 201299
電話: +86 (21) 5859-1500(總機)
傳真: +86 (21) 5859-6369
海外:
Email:?marketing@medicilon.com
Tel: +1 (617) 888-9294(U.S.)
Tel: 0044 7790 816 954 (Europe)
Tel: +82 70-8269-5849 (Korea)
Tel: +81 80-4421-6898 (Japan)